Investigation into Boston Scientific Corporation for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Should l Buy BSX?
Source: Businesswire
- Investigation Announcement: The Law Offices of Frank R. Cruz has initiated an investigation into Boston Scientific Corporation regarding potential violations of federal securities laws, aiming to protect investor rights and pursue claims for losses.
- Disappointing Financial Results: On February 4, 2026, Boston Scientific reported its fourth-quarter 2025 financial results, revealing lower-than-expected sales in its electrophysiology division, which has raised concerns among investors.
- Stock Price Decline: Following the disappointing earnings report, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, significantly impacting investor asset values.
- Investor Rights Advocacy: The law firm is urging investors who purchased Boston Scientific securities to reach out for information on potential claims to recover losses, highlighting the importance of safeguarding investor interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 77.640
Low
112.00
Averages
125.74
High
140.00
Current: 77.640
Low
112.00
Averages
125.74
High
140.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Worst Performing Large-Cap Stocks Last Week
- Stellantis Loss Warning: Stellantis (NYSE:STLA) plummeted 26.24% this week after the company warned of a full-year net loss, significantly eroding investor confidence and potentially impacting future financing capabilities.
- Gartner Earnings Miss: Gartner (NYSE:IT) fell 25.41% this week following the release of its fourth-quarter financial results and a downward revision of its FY26 guidance, with analysts' pessimistic outlook likely to exert further pressure on the stock.
- Reddit Stock Decline: Reddit (NYSE:RDDT) dropped 23.10% this week as multiple analysts lowered their price forecasts, reflecting market concerns over its profitability and potentially hindering its financing and expansion plans.
- Analyst Downgrades: Several analysts adjusted their price targets downward for these companies, indicating a widespread bearish sentiment regarding their future performance, which may lead investors to reassess their portfolios.
See More
Investigation Launched into Boston Scientific's Securities Violations
- Investigation Initiated: The Law Offices of Howard G. Smith has announced an investigation into Boston Scientific for potential violations of federal securities laws, aimed at safeguarding investors' rights.
- Disappointing Earnings: On February 4, 2026, Boston Scientific reported its fourth-quarter 2025 financial results, revealing lower-than-expected sales in its electrophysiology division, which undermined investor confidence.
- Stock Price Plunge: Following the earnings report, Boston Scientific's stock price fell by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, resulting in significant losses for investors.
- Legal Consultation Opportunity: The law firm is urging affected investors to reach out to discuss potential claims for recovery, emphasizing the legal rights and possible compensation avenues available to investors in this matter.
See More
Investigation into Boston Scientific Corporation for Securities Violations
- Investigation Announcement: The Law Offices of Frank R. Cruz has initiated an investigation into Boston Scientific Corporation regarding potential violations of federal securities laws, aiming to protect investor rights and pursue claims for losses.
- Disappointing Financial Results: On February 4, 2026, Boston Scientific reported its fourth-quarter 2025 financial results, revealing lower-than-expected sales in its electrophysiology division, which has raised concerns among investors.
- Stock Price Decline: Following the disappointing earnings report, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, significantly impacting investor asset values.
- Investor Rights Advocacy: The law firm is urging investors who purchased Boston Scientific securities to reach out for information on potential claims to recover losses, highlighting the importance of safeguarding investor interests.
See More
Boston Scientific Analyst Lowers Price Target
- Earnings Beat: Boston Scientific reported revenue of $5.286 billion and adjusted earnings of $0.80 per share, exceeding consensus estimates of $5.280 billion and $0.78 per share, demonstrating resilience in a competitive medical device market.
- Organic Growth Slowdown: The company's organic growth rate declined from 15.3% in Q3 to 12.7%, primarily due to slowing FARAPULSE growth and reduced PFA adoption, reflecting the impact of intensified market competition on business performance.
- Cautious Future Outlook: Management guided for 2026 revenue growth between 10.5% and 11.5%, with a revenue range of $22.182 billion to $22.383 billion, the midpoint falling short of the consensus of $22.370 billion, indicating a cautious stance on future growth.
- Stock Price Reaction: At the time of publication, Boston Scientific's shares rose by 2.08% to $77.07, despite the analyst lowering the price target, suggesting that market confidence in the company's fundamentals remains intact.
See More
Market Turmoil and Corporate Earnings Analysis
- Tech Sector Weakness: S&P futures tumbled due to weakness in Big Tech, with Bitcoin falling below $70,000 for the first time, indicating intensified sell-off in the crypto market that could undermine investor confidence and exacerbate market volatility.
- Job Market Instability: Challenger, Gray & Christmas reported that planned layoffs at American companies hit the highest January total since the global financial crisis, with hiring intentions at their lowest, reflecting the fragility of economic recovery and potential decline in consumer spending.
- Alphabet Price Target Hikes: Following a strong quarterly report, Wall Street analysts raised Alphabet's price targets, yet shares fell over 5% in early trading due to market rotation away from tech, highlighting concerns about future growth amidst competitive pressures.
- Boston Scientific Stock Plunge: Boston Scientific shares sank 17.5% on Wednesday, marking its largest single-day decline in 25 years after disappointing quarterly earnings, although Citi maintained a buy rating, indicating that increased competition could impact its market share.
See More
Texas Instruments Acquires Silicon Labs in $7.5B Deal
- Acquisition Agreement: Texas Instruments is set to acquire Silicon Labs for $231 per share in an all-cash transaction valued at $7.5 billion, which not only boosts Silicon Labs' market valuation but also enhances Texas Instruments' competitive edge in the semiconductor sector.
- Positive Market Reaction: Following the acquisition announcement, Silicon Labs' stock surged by 49%, indicating strong investor confidence in the deal and reflecting optimistic expectations for consolidation within the semiconductor industry.
- Strong Earnings Performance: Silicon Labs reported an adjusted EPS of 56 cents for Q4, slightly above the consensus estimate of 55 cents, demonstrating stable financial performance that enhances the attractiveness of the acquisition.
- Industry Consolidation Trend: This acquisition represents a strategic move for Texas Instruments to expand its product line and signifies an acceleration in semiconductor industry consolidation, potentially triggering more similar deals that could reshape the market landscape.
See More
Worst Performing Large-Cap Stocks Last Week
- Stellantis Loss Warning: Stellantis (NYSE:STLA) plummeted 26.24% this week after the company warned of a full-year net loss, significantly eroding investor confidence and potentially impacting future financing capabilities.
- Gartner Earnings Miss: Gartner (NYSE:IT) fell 25.41% this week following the release of its fourth-quarter financial results and a downward revision of its FY26 guidance, with analysts' pessimistic outlook likely to exert further pressure on the stock.
- Reddit Stock Decline: Reddit (NYSE:RDDT) dropped 23.10% this week as multiple analysts lowered their price forecasts, reflecting market concerns over its profitability and potentially hindering its financing and expansion plans.
- Analyst Downgrades: Several analysts adjusted their price targets downward for these companies, indicating a widespread bearish sentiment regarding their future performance, which may lead investors to reassess their portfolios.
See More
Investigation Launched into Boston Scientific's Securities Violations
- Investigation Initiated: The Law Offices of Howard G. Smith has announced an investigation into Boston Scientific for potential violations of federal securities laws, aimed at safeguarding investors' rights.
- Disappointing Earnings: On February 4, 2026, Boston Scientific reported its fourth-quarter 2025 financial results, revealing lower-than-expected sales in its electrophysiology division, which undermined investor confidence.
- Stock Price Plunge: Following the earnings report, Boston Scientific's stock price fell by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, resulting in significant losses for investors.
- Legal Consultation Opportunity: The law firm is urging affected investors to reach out to discuss potential claims for recovery, emphasizing the legal rights and possible compensation avenues available to investors in this matter.
See More
Investigation into Boston Scientific Corporation for Securities Violations
- Investigation Announcement: The Law Offices of Frank R. Cruz has initiated an investigation into Boston Scientific Corporation regarding potential violations of federal securities laws, aiming to protect investor rights and pursue claims for losses.
- Disappointing Financial Results: On February 4, 2026, Boston Scientific reported its fourth-quarter 2025 financial results, revealing lower-than-expected sales in its electrophysiology division, which has raised concerns among investors.
- Stock Price Decline: Following the disappointing earnings report, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, significantly impacting investor asset values.
- Investor Rights Advocacy: The law firm is urging investors who purchased Boston Scientific securities to reach out for information on potential claims to recover losses, highlighting the importance of safeguarding investor interests.
See More
Boston Scientific Analyst Lowers Price Target
- Earnings Beat: Boston Scientific reported revenue of $5.286 billion and adjusted earnings of $0.80 per share, exceeding consensus estimates of $5.280 billion and $0.78 per share, demonstrating resilience in a competitive medical device market.
- Organic Growth Slowdown: The company's organic growth rate declined from 15.3% in Q3 to 12.7%, primarily due to slowing FARAPULSE growth and reduced PFA adoption, reflecting the impact of intensified market competition on business performance.
- Cautious Future Outlook: Management guided for 2026 revenue growth between 10.5% and 11.5%, with a revenue range of $22.182 billion to $22.383 billion, the midpoint falling short of the consensus of $22.370 billion, indicating a cautious stance on future growth.
- Stock Price Reaction: At the time of publication, Boston Scientific's shares rose by 2.08% to $77.07, despite the analyst lowering the price target, suggesting that market confidence in the company's fundamentals remains intact.
See More
Market Turmoil and Corporate Earnings Analysis
- Tech Sector Weakness: S&P futures tumbled due to weakness in Big Tech, with Bitcoin falling below $70,000 for the first time, indicating intensified sell-off in the crypto market that could undermine investor confidence and exacerbate market volatility.
- Job Market Instability: Challenger, Gray & Christmas reported that planned layoffs at American companies hit the highest January total since the global financial crisis, with hiring intentions at their lowest, reflecting the fragility of economic recovery and potential decline in consumer spending.
- Alphabet Price Target Hikes: Following a strong quarterly report, Wall Street analysts raised Alphabet's price targets, yet shares fell over 5% in early trading due to market rotation away from tech, highlighting concerns about future growth amidst competitive pressures.
- Boston Scientific Stock Plunge: Boston Scientific shares sank 17.5% on Wednesday, marking its largest single-day decline in 25 years after disappointing quarterly earnings, although Citi maintained a buy rating, indicating that increased competition could impact its market share.
See More
Texas Instruments Acquires Silicon Labs in $7.5B Deal
- Acquisition Agreement: Texas Instruments is set to acquire Silicon Labs for $231 per share in an all-cash transaction valued at $7.5 billion, which not only boosts Silicon Labs' market valuation but also enhances Texas Instruments' competitive edge in the semiconductor sector.
- Positive Market Reaction: Following the acquisition announcement, Silicon Labs' stock surged by 49%, indicating strong investor confidence in the deal and reflecting optimistic expectations for consolidation within the semiconductor industry.
- Strong Earnings Performance: Silicon Labs reported an adjusted EPS of 56 cents for Q4, slightly above the consensus estimate of 55 cents, demonstrating stable financial performance that enhances the attractiveness of the acquisition.
- Industry Consolidation Trend: This acquisition represents a strategic move for Texas Instruments to expand its product line and signifies an acceleration in semiconductor industry consolidation, potentially triggering more similar deals that could reshape the market landscape.
See More
